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Abstract
Tenascin C (TNC) is an extracellular matrix protein that is upregulated during development as well as tissue remodeling. TNC
is comprised of multiple independent folding domains, including 15 fibronectin type III-like (TNCIII) domains. The fifth TNCIII
domain (TNCIII5) has previously been shown to bind heparin. Our group has shown that the heparin-binding fibronectin
type III domains of fibronectin (FNIII), specifically FNIII12–14, possess affinity towards a large number of growth factors.
Here, we show that TNCIII5 binds growth factors promiscuously and with high affinity. We produced recombinant
fragments of TNC representing the first five TNCIII repeats (TNCIII1–5), as well as subdomains, including TNCIII5, to study
interactions with various growth factors. Multiple growth factors of the platelet-derived growth factor (PDGF) family, the
fibroblast growth factor (FGF) family, the transforming growth factor beta (TGF-b) superfamily, the insulin-like growth factor
binding proteins (IGF-BPs), and neurotrophins were found to bind with high affinity to this region of TNC, specifically to
TNCIII5. Surface plasmon resonance was performed to analyze the kinetics of binding of TNCIII1–5 with TGF-b1, PDGF-BB,
NT-3, and FGF-2. The promiscuous yet high affinity of TNC for a wide array of growth factors, mediated mainly by TNCIII5,
may play a role in multiple physiological and pathological processes involving TNC.
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Introduction
Tenascin C (TNC) is a complex multifunctional extracellular
matrix (ECM) glycoprotein forming a disulfide-bonded hexabra-
chion. The monomeric unit consists of four major domains
(Figure 1, A) [1,2]. The N-terminal domain mediates hexameriza-
tion by forming a coiled structure with interchain disulfide bonds.
This is followed by a series of 14.5 epidermal growth factor-like
(EGFL) repeats, which are between 30 and 50 amino acids long
and each contain six cysteines; these EGFL repeats have anti-
adhesive properties that encourage migration. The third domain
consists of a series of up to 15 fibronectin type III-like (TNCIII)
repeats, which are approximately 90 amino acids long and form
two sheets of antiparallel b-strands [3]. This region, which
contains several integrin-binding sites that promote cell adhesion,
is subject to extensive alternative splicing, generating many
isoforms [3]. Finally, a fibrinogen-like globular domain is located
at the C terminus.
TNC is a multifaceted protein that is expressed throughout
development and is present within healthy adult tissues at low
levels [4,5,6]. In addition, TNC is expressed in adults under tight
spatio-temporal control during tissue remodeling, such as wound
healing [7] and nerve regeneration [8], as well as during
inflammation [2]. During development, TNC plays a highly
regulated and dynamic role in the patterning of the skeletal, neural
and vascular systems [3]. TNC has been shown to affect cell
adhesion, proliferation, and migration [3] and to modulate stem
cell behavior [1]. During physiological wound repair, TNC is
produced in a tightly controlled, rapid, and transient manner.
However, uncontrolled TNC production has been observed in
cases of abnormal tissue growth associated with cancer [9], fibrotic
diseases, chronic wounds, cardiovascular diseases [10,11], auto-
immune diseases [2], and restenosis after percutaneous coronary
angioplasty [12] and stent implantation [13]. Recently, TNC has
also been implicated in cardiac and arterial inflammation, tumor
angiogenesis and metastasis [14,15].
TNC has been extensively studied and found to interact directly
with a variety of cell types through binding to integrins, heparan
sulfate proteoglycans, and other cellular receptors as well as
indirectly via binding to fibronectin [16,17]. The location of the
heparin-binding domain has been mapped to the fourth and
principally fifth TNCIII domain [17,18]. Recently, our group has
demonstrated that a similar heparin-binding fibronectin type III
region within fibronectin (FNIII), FNIII12–14, binds a large
number of growth factors with high affinity [19].
The observation of promiscuous growth factor binding to
FNIII12–14 described above motivated us to examine potential
growth factor interactions with TNC, specifically within its
heparin-binding region. Here, we report that the heparin-binding
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region of TNC has a high affinity towards a large number of
growth factors from the vascular endothelial growth factor
(VEGF)/platelet-derived growth factor (PDGF), fibroblast growth
factor (FGF), transforming growth factor-b (TGF-b) and neuro-
tropin families, as well as from the insulin-like growth factor-
binding proteins (IGF-BPs), with nanomolar binding affinities. The
finding that TNC has the ability to bind growth factors and that
the fifth TNCIII domain (TNCIII5) plays a major role in its
binding activity may have important implications in the functions
of this dynamic ECM protein in (patho)biology.
Methods
Production of tenascin C fragments
Human TNCIII1–5 was expressed in mammalian cells, HEK-
293E, using the vector pSecTag A (Invitrogen), which uses an Ig
kappa leader sequence for secretion of the TNC fragment. A SfiI
cloning site, which codes for the amino acids AAQPA, follows the
signal sequence. Immediately after the cloning site, a factor Xa
cleavage site was introduced to allow for complete removal of the
leader peptide. A transglutaminase (TG) substrate, residues 1–8
of alpha2-plasmin inhibitor (NQEQVSPL), was designed to
follow the factor Xa cleavage site and thus be present at the N-
terminus of the mature, secreted protein. A short linking
sequence of GGS was added before the addition of the
TNCIII1–5, namely residues E622 to A1074 of TNC. At the
C-terminus of the construct is a short linker sequence, GGGS,
followed by a 6xHis tag (Figure 1, C).
HEK-293E cells were transfected with 1.25 mg of plasmid per
105 cells per 1 mL of final growth medium (Excell 293, 4 mM
glutamine, 3.75 mM valproic acid). The culture medium was
harvested after 7 days of shaker flask expression and cells were
removed by filtration. The protein was then purified using an
FPLC (Akta Explorer, GE Healthcare) with a HisTrap HP column
(GE Healthcare). After elution of the protein, the buffer was
changed by dialysis in tris buffer (20 mM Tris-HCl, 150 mM
NaCl, pH 7.4). The lipopolysaccharide (LPS) levels were detected
with a HEK-BlueTM LPS Detection Kit (InvivoGen).
The flanking amino acids of the domains produced from TNC
are shown within parenthesis. Genes for GST-TNCIII3 (T801–
T891), GST-TNCIII4 (T891–T983), GST-TNCIII5 (T983–
A1074), GST-TNCIII3-4 (T801–T983), GST-TNCIII4-5
(T891–A1074), and GST-TNCIII3-5 (T801–A1074) were cloned
into pGEX-6p-1 using BamHI and EcoRI restriction sites and
DH5alpha E. coli. Each gene sequence was verified using capillary
sequencing services (Fasteris). Proteins were expressed in BL21 E.
coli and purified using Ni–NTA agarose (Qiagen) according to
manufacturers instructions. The proteins were dialyzed into
phosphate buffered saline (PBS, Invitrogen), pH 7.4. The TNC
fragments were run on a SDS-PAGE gel and stained with
SimplyBlue (Invitrogen).
Figure 1. Production and characterization of TNCIII1-5. (A) Top: schematic of structural domains of full length human tenascin C (TNC), with
major integrin binding and heparin binding domains. Bottom: schematic of the designed TNCIII1-5 fragment. (B) SDS-PAGE gel of purified TNCIII1–5
with the molecular weight of 53 kD, and the different GST-TNCIII (fusion) domains (GST-TNCIII3, GST-TNCIII4, GST-TNCIII5, GST-TNCIII3-4, GST-TNCIII4-
5, GST-TNCIII3-5). (C) Amino acid sequence of TNCIII1–5. (D) Graphical depiction of isoelectric points of the TNCIII domains.
doi:10.1371/journal.pone.0062076.g001
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The protein pI of the different TNCIII domains is a theoretical
calculation using the residues from each TNCIII domain and the
pK values of amino acids described in Bjellqvist et al. [20]
Full-length TNC was purchased from (AdB serotech), and SDS-
PAGE confirmed its purity and molecular weight.
Detection of growth factor binding via ELISA
To detect binding of TNCIII1-5 to growth factors, growth
factors of human sequence (at 50 nM in PBS) (VEGF-A165
(Invitrogen), PDGF-BB (Gibco), others (Peprotech)) were coated
on an ELISA plate (1 h, 37uC). After blocking with 2% bovine
serum albumin (BSA, Sigma) (1 h, RT), 100 nM TNCIII1-5 was
applied in PBS containing 0.05% tween and 0.1% BSA (PBST)
(1 h, RT). TNCIII1-5 was detected with horseradish peroxidase
(HRP)-anti-HIS (Abcam) in PBST (4 min, RT), developed with
3,39,5,59-tetramethylbenzidine (TMB) (eBioscience), stopped by
sulfuric acid stop solution, and measured at 450 nm using a plate
reader (A450) (Safire II, Tecan). Binding of TNCIII1-5 was
analyzed with and without the presence of heparin (4 mM)
(average MW of 15 kDa, Sigma). The plotted data is the A450
value of TNCIII1-5 binding subtracted by the A450 value in the
absence of TNCIII1-5. An absorbance reading over 0.1 was
considered as a significant interaction. To verify absorbance to the
ELISA plate, a selection of growth factors that did not show
binding to TNC III1–5 was detected with their respective
antibodies.
Competition assays
To analyze the binding of growth factors to TNCIII1–5 in the
presence of heparin and the cross-competition between TNCIII1–
5 and full length native human TNC (AbDSerotech) to bind
growth factors, ELISA plates were coated with 50 nM growth
factor (1 h, 37uC), blocked with 2% BSA (1 h, RT), and further
incubated with 10 nM TNCIII1–5 in PBST in the presence of a
gradient of heparin (0.01, 0.64, 3.2, 16, 80, 400, 2000, and
10000 nM) or full length TNC (0, 0.2, 0.6, 1.9, 5.6, 17, 50 nM)
(1 h, RT). TNCIII1–5 was detected with HRP-anti-HIS in PBST
(45 min, RT) and developed with TMB. Background values were
obtained by applying heparin or TNC at the respective
concentration in the absence of TNCIII1–5 and subtracted from
the A450 value of TNCIII1–5 binding. The plotted data is the
binding of TNCIII1–5 relative to TNCIII1–5 binding in the
absence of heparin or TNC.
Binding of 10 nM TNC to growth factors of different families,
namely PDGF-BB, BDNF, VEGF-A165, FGF-2 and BMP-2, was
detected with mouse anti-TNC (1:2,000, 45 min, RT) (Abcam,
Cambridge, UK), a secondary HRP conjugated anti-mouse
antibody (1:2,000, 45 min, RT) (Dako), and TMB. TNC binding
was analyzed and plotted after subtraction of the levels obtained
without TNC.
Surface plasmon resonance to quantify affinity values
Measurements were made using a Biacore X100 surface
plasmon resonance instrument (GE Healthcare). TNCIII1–5 was
immobilized in one channel using the amine coupling kit on a
carboxylated gold chip (Sensor Chip C1; GE Healthcare), while
BSA was similarly immobilized to the control channel. Approx-
imately 450 RU of TNCIII1–5 was coupled to the chip according
to the manufacturer’s instruction. The reaction was quenched
using 1 M ethanolamine. BSA was functionalized to the control
channel at approximately 700 RU using the same method. After
quenching of the reactive groups, PBS with 1% BSA was flowed
over both channels to block any nonspecific interactions. Growth
factors were diluted in the running buffer (PBS with 0.1% BSA)
and delivered at a flow rate of 30 ml/min. PDGF-BB, FGF-2 and
TGF-b were flowed at increasing concentrations from 0.4 nM to
33 nM, using 3-fold dilutions; NT-3 was flowed at increasing
concentrations from 1.23 nM to 100 nM, using 3-fold dilutions.
Binding constants of growth factors to TNCIII1–5 were automat-
ically calculated using BIAevaluation software Biacore X100 (GE
Healthcare) fitted using Langmuir binding kinetics.
Identification of domains in TNCIII1–5 responsible for
binding growth factors
A sandwich ELISA was performed to test the affinity of different
domains present in TNCIII1–5 to PDGF-BB. The domains tested
were GST-TNCIII3, GST-TNCIII4, GST-TNCIII5, GST-
TNCIII3-4, GST-TNCIII4-5, and GST-TNCIII3-5. ELISA
plates were coated with 50 mL of each domain (1 mM) in PBS,
as well as GST only and BSA (1 h, 37uC). Wells were blocked
using PBS with 2% BSA (1 h, RT) and then incubated with 2 nM
PDGF-BB (1 h, RT). Binding of PDGF-BB was detected using an
anti-PDGF-BB antibody (R&D, Minneapolis, MN) (1:2,000,
45 min, RT), a secondary HRP conjugated anti-mouse antibody
(1:2,000, 45 min, RT), and TMB.
Results
Production of TNC fragments
The TNC fragment TNCIII1–5 engineered with a TG
substrate domain and a HIS tag was produced by mammalian
expression, resulting in a protein with a molecular weight of
approximately 53 kDa (Figure 1, B). The amino acid sequence can
be found in Figure 1C. The TG substrate domain allows
immobilization within fibrin matrices if desired [21]. The LPS
levels were below the detection limit (0.3 ng/ml).
The individual domains TNCIII3, TNCIII4, and TNCIII5,
and various combinations, TNCIII3–4, TNCIII4–5, and
TNCIII3–5, were expressed by bacterial expression as GST
fusions and purified using a C-terminal HIS tag. GST was used as
a fusion protein because it may stabilize the individual TNCIII
domains (Figure 1, B).
Calculation of the isoelectric points of the different TNCIII
domains revealed that most domains have a pI around 4, while
TNCIII4 and TNCIII5 have a pI of 8.25 and 9.57, respectively
(Figure 1, D). This correlates with their ability to bind highly
negatively charged heparin, similarly to the FNIII12–14 domains
of fibronectin [22], which also possess pIs between 9 and 10.
Binding of TNCIII1–5 to growth factors
An indirect ELISA method was used to screen binding of
growth factors to TNCIII1–5 in a semi-quantitative manner, both
in the absence of heparin and with excess (4 mM) heparin. In total,
43 growth factors plus two growth factor-binding proteins were
screened, of which 23 growth factors and both growth factor-
binding proteins were shown to bind (Figure 2). In general, excess
heparin greatly reduced the binding interactions.
Many members from the PDGF/VEGF family, including
PDGF-AA, PDGF-AB, PDGF-BB, PDGF-DD, VEGF-A165,
VEGF-B, VEGF-C, PlGF-2, and PlGF-3 demonstrated binding
to TNCIII1–5 (Figure 2, A). Whereas VEGF-A165 bound, its
shorter splice variant VEGF-A121 did not, and whereas PlGF-2
and -3 bound, their shorter splice variant PlGF-1 did not.
From the FGF family, FGF-2, FGF-4, FGF-6, FGF-7, FGF-8,
FGF-10, FGF-17, and FGF-18 demonstrated binding to TNCIII1-
5 (Figure 2, B). Whereas FGF-2 (also known as basic fibroblast
growth factor, bFGF) bound, FGF-1 (also known as acidic
fibroblast growth factor, aFGF) did not.
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Of the TGF-b family, TGF-b1 and TGF-b2, but not TGF-b3,
bound to TNCIII1–5. Bone morphogenetic protein (BMP)-2
showed binding, but BMP-4, -6 or -7 did not bind (Figure 2, C).
From the insulin-like growth factor (IGF) family, although the
growth factors IGF-1 and IGF-2 themselves did not bind, the high-
affinity IGF-binding proteins IGF-BP3 and IGF-BP5 showed
binding to TNCIII1–5 (Figure 2, D).
Of the neurotrophic factors, neurotrophin-3 (NT-3), brain-
derived growth factor (BDNF), and nerve growth factor (NGF)
were tested. Both NT-3 and BDNF were found to bind to
TNCIII1–5, whereas NGF did not.
Furthermore, connective tissue growth factor (CTGF), epider-
mal growth factor (EGF), and heparin-binding EGF-like growth
factor (HB-EGF) did not bind TNCIII1–5, but hepatocyte growth
factor (HGF) did show affinity for TNCIII1–5 (Figure 2, E).
The effect of excess heparin on the binding of growth factors to
TNCIII1–5 was also tested using the indirect ELISA, in the
presence of a 40-fold excess (compared to TNCIII1–5) of heparin
(4 mM) during incubation with TNCIII1–5 (100 nM). Binding of
TNCIII1–5 to nearly all growth factors was greatly reduced in the
presence of excess heparin. Only two growth factors retained more
than 50% of their binding to TNCIII1–5, namely BMP-2 and NT-
3, which retained 66% and 57% of there original binding,
respectively (Figure 2). Growth factors of different families (e.g.,
VEGF-A121, PlGF-1, FGF-1, NGF) that did not bind TNCIII1–5
were verified to absorb to the ELISA plate using their respective
antibodies and were easily detected, showing significant binding
over background levels (Figure S1).
Competition assay between heparin and growth factors
to bind TNCIII1–5
To further investigate the influence of heparin on growth factor
binding to TNCIII1–5, the indirect ELISA described above was
used to measure binding at different concentrations of heparin.
Selected growth factors of different families, namely PDGF-BB,
VEGF-A165, FGF-2 and BDNF, were analyzed. A fixed amount
of TNCIII1–5 (10 nM) was added with various dilutions of
heparin (0.01 nM to 10,000 nM). At low concentrations of
heparin, growth factor binding to TNCIII1–5 was enhanced by
heparin addition, but with increasing concentrations of heparin,
growth factor binding was diminished. The maximum binding of
PDGF-BB and VEGF-A165 was in the presence of heparin at
16 nM and 0.64 nM, respectively (Figure 3, A–B), while
maximum binding for FGF-2 and BDNF were observed at a
heparin concentration of 3.2 nM (Figure 3, C–D); in all
experiments, TNCIII1–5 was at 10 nM. High excesses of heparin,
say 1000-fold (i.e., 10 mM), blocked essentially all growth factor
binding to TNCIII1–5.
Cross-competition assay between TNCIII1–5 and full
length TNC
To determine if full-length TNC shares the same binding site as
the TNC fragment TNCIII1–5, a cross-competition ELISA was
performed with increasing concentrations of TNC (0 nM to
50 nM) at a fixed concentration of TNCIII1–5 (10 nM). First,
binding of full-length TNC (10 nM) to growth factors of different
families, namely PDGF-BB, BDNF, VEGF-A165, FGF-2 and
Figure 2. Identification of growth factors with an affinity towards TNCIII1–5. Binding of TNCIII1–5 to growth factors of different families,
measured using indirect ELISA. Binding was measured in the presence of 4 mM heparin (grey) and in its absence (black). Various growth factor families
were tested, PDGF/VEGF family (A), FGF family (B), TGF-b family (C), IGF family and IGF-BPs (D), and others (E) (n = 3, mean6SD).
doi:10.1371/journal.pone.0062076.g002
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BMP-2, was verified (Figure 4, A). Second, binding of different
doses of TNC to PDGF-BB (with BSA as a control) was
performed, and specific binding of the full-length protein was
observed (Figure 4, B). In the cross-competition assay, TNC was
found to reduce binding of TNCIII1–5 to PDGF-BB, BDNF,
FGF-2 and VEGF-A165, but only marginally inhibited binding to
BMP-2. Approximately 50% inhibition of TNCIII1–5 binding to
PDGF-BB, BDNF, and VEGF-A165 was seen in the presence of
17 nM full-length TNC (Figure 4, C–E), while approximately 50%
inhibition towards FGF-2 occurred at 5.6 nM of TNC (Figure 4,
F). These values, close to 1:1 with the 10 nM TNCIII1–5 used in
the experiment, suggest that the binding of most of the growth
factors to the fragment TNCIII1–5 properly represents binding to
the native structure within full-length TNC. However, the lack of
50% inhibition even at 50 nM TNC (a 5-fold excess, at which
34% inhibition occurred) for BMP-2 suggests that in some
instances, the interactions may be more complex (Figure 4, G).
Surface plasmon resonance to quantify affinity values
Surface plasmon resonance (SPR) was used to determine the
equilibrium binding constants (KD) for selected growth factors
(TGF-b1, PDGF-BB, NT-3 and FGF-2) from four different
families (Figure S2). The affinities for both TGF-b1 and NT-3
were approximately 20 nM (Table 1). For PDGF-BB and FGF-2,
the sensorgrams did not fit Langmuir kinetics, displaying a non-
standard kinetic profile.
Identification of domains within TNCIII1-5 responsible for
binding growth factors
Individual domains of TNC (TNCIII3, TNCIII4, TNCIII5)
and various combinations (TNCIII3–4, TNCIII4–5, TNCIII3–5)
were expressed as GST fusions to identify which domains are
responsible for growth factor binding, using PDGF-BB as an
exemplary growth factor (Figure 5). The TNCIII3 showed no
binding to PDGF-BB. TNCIII4 showed binding to PDGF-BB at a
modest level, as did TNCIII3–4. By contrast, TNCIII5 showed
high binding levels, 4-fold that of TNCIII4. Other combinations
containing TNCIII5, namely TNCIII4–5 and TNCIII3–5, also
showed high binding levels. When the GST fusion of these
proteins was removed, the binding was significantly reduced (data
not shown), which led us to hypothesize that the GST fusion may
stabilize the folding of the TNCIII domains in a similar manner as
observed with other fusion protein that stabilize the protein
partner [23,24]. Therefore, we produced TNCIII1–5 in order to
generate a protein comprised of only domains from TNC and still
maintain binding to growth factors, independent of a GST
stabilizing domain.
Based on these results, we may conclude that within the
TNCIII1–5 growth factor-binding fragment, binding is principally
localized in the TNCIII5 domain.
Discussion
The extracellular microenvironment is composed of numerous
matrix-forming proteins that serve multiple functions, such as
structural control and integrin binding for cellular stability. An
Figure 3. The effect of heparin concentration on the ability of TNCIII1–5 to bind selected growth factors. Using ELISA, the binding of
TNCIII1–5 (10 nM) to various growth factors (A) PDGF-BB, (B) VEGF-A165, (C) FGF-2, and (D) BDNF was measured in the presence of increasing
concentrations of heparin, 0.01 nM to 10,000 nM, with 100% representing binding of 10 nM TNCIII1–5 without the presence of heparin. The binding
of the growth factors to TNCIII1–5 reached a maximum at an intermediate heparin concentration for all growth factors tested (n = 3, mean6SD).
doi:10.1371/journal.pone.0062076.g003
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increasingly observed role of ECM proteins is the ability to bind
and sequester growth factors, acting as a reservoir for the
stimulatory molecules that can be released during proteolytic
remodeling of wounded areas [25,26]. Additionally, an emerging
concept for the role of growth factor binding within the ECM is
the enhancement of cellular signaling through co-association of
integrins and growth factor receptors [27].
In a recent report from our group, we showed that the FNIII12–
14 domain of fibronectin possessed a highly promiscuous growth
factor-binding ability [19]. FNIII12–14 was initially established as
a heparin-binding domain [22], and later it was observed that the
domain also binds VEGF-A165 [28]. Interestingly, TNCIII4–5 is
also a known heparin-binding domain [17,18], so we hypothesized
that this domain may also bind a wide-range of growth factors.
Human TNCIII1–5, indeed, demonstrated strong binding to
many growth factors from different families; binding was located
principally to TNCIII5, but TNCIII4 also contributed to the
interaction. The cross-competition assay between TNCIII1–5 and
full-length TNC confirmed that TNC can specifically block the
interaction of the TNC subdomain with growth factors.
Even though FNIII12–14 and TNCIII1–5 are both, respec-
tively, fibronectin type III and fibronectin type III-like repeats that
bind heparin and interact with many of the same growth factors,
there are also many growth factors that interact with only one of
Figure 4. Full-length TNC and TNCIII1–5 cross-competition ELISA. Testing of binding of full length TNC to a selection of growth factors and
cross-competition binding assay of TNC with TNCIII1–5. (A) Binding of TNC (10 nM) to PDGF-BB, BDNF, VEGF-A165, FGF-2, and BMP-2. (B) An
increasing dose of full length TNC (0 to 50 nM) resulted in higher binding levels of TNC to PDGF-BB (black). No specific binding to BSA (grey) was
observed. (C–G) Cross-competition assay between full length TNC and TNCIII1–5 (10 nM) to bind selected growth factors: PDGF-BB (C), BDNF (D),
VEGF-A165 (E), FGF-2 (F), and BMP-2 (G). The TNC concentration varied from 0.1 nM to 50 nM (n= 3, mean6SD), with 100% representing binding of
10 nM TNCIII1–5 without the presence of TNC.
doi:10.1371/journal.pone.0062076.g004
Table 1. Equilibrium binding constants (KD), and association
(kon) and dissociation (koff) rates were determined using
surface plasmon resonance (SPR) and fitting the data to
Langmuir binding kinetics for binding of immobilized TNCIII1–
5 to TGF-b1 and NT-3.
Growth factor kon (1/Ms) koff (1/s) KD (nM)
TGF-b1 1.17E+04 2.37E204 20.3
PDGF-BB NA* NA* NA*
NT-3 5.07E+04 1.06E203 21.0
FGF-2 NA* NA* NA*
*Not applicable (NA) because the data was not interpretable using standard
Langmuir binding kinetics for FGF-2 and PDGF-BB.
doi:10.1371/journal.pone.0062076.t001
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the domains. FNIII12–14 has been shown to bind to PDGF-CC,
BMP-7, FGF-9, and CTGF, while TNCIII1–5 did not have a
significant interaction with any of these growth factors. Converse-
ly, TGF-b2 was found to bind to TNCIII1–5, which was reported
to not interact with FNIII12–14 [19]. The biological significance
of these differences is not known but could play a role in patterning
of growth factors within the ECM, thus creating unique
microenvironments for various cell types.
Additionally, an observed difference between growth factors
that bound to TNCIII1–5 and those that did not was the presence
of a heparin-binding domain within the growth factors. For
example, VEGF-165 and PlGF-2, which contain a heparin-
binding domain, were found to bind to TNCIII1–5, while VEGF-
121 and PlGF-1, which lack a heparin-binding domain, did not.
Because the heparin binding domains on both the growth factors
and TNCIII1–5 are positively charged, the interactions cannot be
attributed to simple charge-charge interactions. However, not all
heparin binding growth factors interacted with TNCIII1–5, for
example, FGF-1 and HB-EGF.
SPR was used to analyze the kinetics of binding of four selected
growth factors from different families, namely PDGF-BB, NT-3,
TGF-b1, and FGF-2. Both TGF-b1 and NT-3 displayed
equilibrium dissociation constants of approximately 20 nM. The
binding parameters of PDGF-BB and FGF-2 could not be
determined using Langmuir kinetics because of the non-standard
kinetic profile of the sensorgram curves. The kinetic profile could
be the result of a complex binding interaction of the growth factors
to the TNCIII domains, which may be due to different
conformational changes induced during the binding, similar to
those observed upon FNIII binding interactions of fibronectin
[29]. The reported affinities of the examined growth factors
towards FNIII12–14 [19] were slightly higher than those
measured for TNCIII1–5, but generally within the same order
of magnitude.
Interestingly, heparin plays a complex role in the interaction of
growth factors to TNCIII1–5. At approximately equimolar
concentrations of heparin and TNCIII1–5, the binding interaction
was enhanced. For PDGF-BB and VEGF-A165, this effect
increased binding by more than 2-fold. At greater concentrations
of heparin, growth factor binding was reduced and was almost
negligible at the maximum concentration of 10 mM heparin.
Heparin has been reported to induce conformational changes
within the heparin-binding domain of fibronectin, resulting in
enhanced binding of VEGF-A165 [29] and PDGF-AA [30]. In
addition, FNIII12–14 demonstrated enhanced binding for almost
all binding growth factors with an excess of heparin [19]. Heparin
may play a similar role in the binding interaction between
TNCIII1–5 and growth factors, although in the case TNCIII1–5,
heparin was found to significantly inhibit the binding at higher
concentrations, in contrast to the behavior observed for FNIII12–
14 [19].
The close proximity of an integrin-binding domain and a
growth factor-binding domain within fibronectin causes the
cooperative cellular signaling in response to fibronectin-binding
growth factors [27]. A synergistic interaction has also been
observed for VEGF-A165 [31], PDGF-AA [30], and PDGF-BB
[32] with fibronectin, and for PDGF-BB with TNC [33]. Similarly
to fibronectin, the growth factor-binding domain of TNC we
identified is located proximal to an important integrin-binding
domain, TNCIII3, which is known to bind integrins such as a8b1
and avb3 [3]. These proximal interactions may explain the
observation that TNC enhances PDGF-BB-induced proliferation
and migration of smooth muscle cells by promoting crosstalk
signaling between the PDGF-BB receptor (PDGF Rb) and integrin
avb3 [33].
Even though the complete gene knockout of TNC has minimal
phenotype in mice [34,35], more recent studies revealed several
defects in TNC knockout mice in the case of pathological
intervention [36]. Growth factor binding to extracellular matrix
components is a highly redundant phenomenon; for example
fibronectin and collagen have been demonstrated to show relevant
binding to growth factors [19,37]. Therefore, we believe that the
finding that tenascin binds growth factors may play an important
role in multiple physiological and pathological processes that were
not necessarily observed in the TNC knockout animals, but where
tenascin does play a role. TNC plays an active role in
development, nerve growth, cancer, and wound healing, and thus
may be involved in the regulation and signaling of growth factors
to control cell proliferation and differentiation, as well as signaling
directly through its multiple integrin binding domains. For
example, S100A4(+) fibroblasts have been reported to play a role
in metastatic colonization due to their production of both VEGF-
A165 and TNC [14]. Based on the interactions identified herein,
there may be an important relationship between TNC and VEGF-
A165 affecting metastatic colonization. Additionally, it has
recently been reported that lower levels of TGF-b1 and reduced
epithelial-mesenchymal transition (EMT) were observed after eye
lens injury in TNC2/2 mice [38]. This observation may be related
to the ability of TNC to bind to TGF-b1, which could locally
sequester the growth factor at the site of injury.
TNC has been shown to play a broad role in pathophysiology
[11], and our observation of a promiscuous interaction with
growth factors suggests that molecular interactions between TNC
and growth factors may be important in this role. Recently, it has
been shown that breast cancer cells producing TNC promote the
survival and outgrowth of pulmonary micrometastases by
enhancing the expression of stem cell signaling components [15].
It has been suggested that TNC may promote cell dissemination
and survival during early tumor metastasis by sequestering growth
factors, ECM molecules, enzymes, cell surface receptors and
integrins [39], even though specific binding of growth factors to
TNC had not yet been reported. The identification of the TNC
Figure 5. Determination of the specific growth factor-binding
domain. The binding affinity of different (fusion) domains (GST-TNCIII3,
GST-TNCIII4, GST-TNCIII5, GST-TNCIII3-4, GST-TNCIII4-5, GST-TNCIII3-5)
to PDBF-BB was determined and compared to controls, GST only and
BSA, using an indirect ELISA method. The TNC domain responsible for
growth factor binding was mainly identified as domain TNCIII5, with
TNCIII4 contributing to a lesser extent. (n = 3, mean6SD).
doi:10.1371/journal.pone.0062076.g005
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growth factor-binding domain opens new opportunities to
investigate its role in disease.
In addition, the promiscuous binding of growth factors to TNC
could play an important role during development and tissue repair
when TNC is upregulated at the site of injury. The production and
use of specific functional TNC domains may therefore be
attractive in the field of tissue engineering to create biomimetic
materials [26,40]. Scaffolds could be modified with these
engineered TNC fragments to function as cell signaling platforms
or drug delivery devices by retaining and presenting growth factors
within the matrix [41,42], as our group has done with functional
FN fragments [27].
Conclusion
In this report, we found that TNC binds growth factors via its
fourth and principally fifth fibronectin type III-like domain with
nanomolar affinity. TNCIII1–5 was produced and shown to bind
a wide variety of growth factors from different families, including
the PDGF family, the FGF family, the TGF-b superfamily, and
neurotrophins, in addition to the IGF-BPs. This promiscuous
affinity for growth factors from diverse families may be related to
the broad role played by TNC in both tissue repair and disease.
Supporting Information
Figure S1 Growth factor detection on ELISA plate.
Growth factors of different families (e.g., VEGF-A121, PlGF-1,
FGF-1, NGF) that did not bind TNCIII1-5 were verified to absorb
to the ELISA plate, showing significant binding over background
levels.
(TIF)
Figure S2 Affinity measurement of TNCIII1-5 to repre-
sentatives from four growth factors families. Surface
plasmon resonance measurements to quantify affinity values were
made using a Biacore X100 surface plasmon resonance instru-
ment. TNCIII1-5 was immobilized in one channel, while BSA was
similarly immobilized to the control channel. Growth factors were
diluted in the running buffer (PBS with 0.1% BSA) and delivered
at a flow rate of 30 ml/min. (A) TGF-b1, (B) PDGF-BB and (D)
FGF-2 and were flowed at increasing concentrations from 0.4 nM
to 33 nM, using 3-fold dilutions; (C) NT-3 was flowed at
increasing concentrations from 1.23 nM to 100 nM, using 3-fold
dilutions. Binding constants of growth factors to TNCIII1-5 were
automatically calculated using BIAevaluation software Biacore
X100 (GE Healthcare) fitted using Langmuir binding kinetics.
(TIF)
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